Cost-analysis of four diagnostic strategies for Pneumocystis carinii pneumonia in HIV-infected subjects.
The aim of this study was to analyse the cost-effectiveness ratio of four diagnostic strategies for Pneumocystis carinii pneumonia (PCP) in patients infected with human immunodeficiency virus (HIV). Two hundred and ten HIV-infected patients with suspected PCP underwent induced-sputum (IS) followed, if negative, by bronchoalveolar lavage (BAL); 85 of these patients were able to undergo an exercise test (ET), prior to induced sputum and BAL. The following strategies were analysed: BAL strategy (BAL whenever PCP is suspected); IS strategy (induced sputum followed by BAL if negative); exercise test (ET) strategy, (ET followed by BAL if the results are abnormal); and the ES (exercise sputum) strategy (i.e. BAL only after abnormal ET and negative IS). The cost of each strategy was calculated by taking into account only direct costs; the conditions in which two given strategies would be cost-equivalent were also evaluated. The prevalence of PCP in this population was 31%; IS had 100% specificity and 71% sensitivity, whilst ET had 100% sensitivity and 77% specificity. The costs of BAL, IS, ET and ES strategies were 210,000, 191,940, 140,700 and 112,700 FF, respectively. The ES strategy is, thus, most suitable for our unit. The most economic strategy depends not only on the cost and characteristics of the procedures, but also on the prevalence of PCP in the test population. In conclusion, we developed a model for use by diagnostic centres in choosing the most suitable strategy, on the basis of the local prevalence of PCP.
Chouaid
C
C
Service de Pneumologie, Hôpital Saint Antoine, Paris, France.
Housset
B
B
Lebeau
B
B
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis*; D018893:Bronchoalveolar Lavage / Q000191:economics / Q000379:methods; D019411:Clinical Laboratory Techniques / Q000191:economics*; D003365:Costs and Cost Analysis; D005080:Exercise Test / Q000191:economics / Q000379:methods; D005602:France; D006801:Humans; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis*; D015995:Prevalence; D012129:Respiratory Function Tests / Q000191:economics*; D012680:Sensitivity and Specificity; D013183:Sputum / Q000382:microbiology